HB Wealth Management LLC Raises Holdings in Leap Therapeutics, Inc. (NASDAQ:LPTX)

HB Wealth Management LLC increased its stake in Leap Therapeutics, Inc. (NASDAQ:LPTX) by 103.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,500 shares of the company’s stock after purchasing an additional 26,150 shares during the period. HB Wealth Management LLC owned 0.13% of Leap Therapeutics worth $150,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Simplify Asset Management Inc. boosted its position in Leap Therapeutics by 67.4% in the third quarter. Simplify Asset Management Inc. now owns 1,056,895 shares of the company’s stock valued at $2,716,000 after buying an additional 425,626 shares during the last quarter. Exome Asset Management LLC acquired a new stake in Leap Therapeutics during the 3rd quarter valued at approximately $264,000. Marshall Wace LLP boosted its holdings in Leap Therapeutics by 268.2% in the second quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after purchasing an additional 58,094 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Leap Therapeutics by 18.0% in the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after buying an additional 50,194 shares during the period. Finally, Key Client Fiduciary Advisors LLC boosted its stake in shares of Leap Therapeutics by 13.0% in the third quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock worth $827,000 after buying an additional 37,067 shares during the last quarter. Hedge funds and other institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Trading Down 2.3 %

Leap Therapeutics stock opened at $2.15 on Friday. The company has a 50-day moving average price of $2.91 and a 200 day moving average price of $2.78. The stock has a market cap of $82.38 million, a P/E ratio of -1.11 and a beta of 0.17. Leap Therapeutics, Inc. has a 12-month low of $1.68 and a 12-month high of $4.79.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.50 price objective on shares of Leap Therapeutics in a research report on Thursday, January 16th.

Leap Therapeutics Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.